USA - NASDAQ:ADXN - US00654J2069 - ADR
Taking everything into account, ADXN scores 1 out of 10 in our fundamental rating. ADXN was compared to 192 industry peers in the Pharmaceuticals industry. ADXN may be in some trouble as it scores bad on both profitability and health. ADXN does not seem to be growing, but still is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -66.46% | ||
| ROE | -78.38% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -50.28 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.31 | ||
| Quick Ratio | 2.31 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:ADXN (10/27/2025, 8:02:12 PM)
9.9213
+0.32 (+3.35%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 14.97 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.17 | ||
| P/tB | 1.17 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -66.46% | ||
| ROE | -78.38% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.31 | ||
| Quick Ratio | 2.31 | ||
| Altman-Z | -50.28 |
ChartMill assigns a fundamental rating of 1 / 10 to ADXN.
ChartMill assigns a valuation rating of 0 / 10 to ADDEX THERAPEUTICS LTD (ADXN). This can be considered as Overvalued.
ADDEX THERAPEUTICS LTD (ADXN) has a profitability rating of 0 / 10.
The financial health rating of ADDEX THERAPEUTICS LTD (ADXN) is 3 / 10.
The Earnings per Share (EPS) of ADDEX THERAPEUTICS LTD (ADXN) is expected to decline by -1500% in the next year.